|
Of 85 ptients who did not achieve undetectable hcv rna or 2 log10 reduction in hcv rna at 12 weeks 2 ; had a sustained viral response.
Before using rabeprazole : some medical conditions may interact with rabeprazole.
The Covance facility in Chandler will test drugs that have not yet been approved by the FDA. Some of these drugs will represent entirely new classes of pharmaceuticals for which treatment technologies may or may not exist. Chandler residents will not only be burdened with initial investments in sewage-treatment technologies in order to remove pharmaceutical contamination, but also with continual updates to these technologies in order to handle new classes of drugs. sandiego.gov water waterreusestudy pdf 060130 - "Orange County [California] is spending $500 million" : whqlibdoc.who.int bulletin 2003 Vol81-No10 bulletin 2003 81 10 ; 768-769 copy & paste ; - "Advanced water treatment technologies . can remove drugs from potable water . Municipal wastewater is never treated in this way because of a lack of suitable technology and the high economic investment required. Furthermore, the large numbers of different compounds that are released and the wide range of their properties and effects mean that comprehensive, large-scale monitoring programmes to test for the compounds would be extremely expensive and time-consuming.
Generic-makers fail in bid to force drug firms to sue over unresolved patents due to the continued lack of reasonable apprehension, the generics industry has lost its bid to block the right of brand-name pharmaceutical companies to refuse to sue them for patent infringement when the fda considers an abbreviated new drug application anda, for example, rabeprazole intermediates.
Presentations and workshops will include: Consent and medical law Poisoning and overdose in children Decontamination of patients after accidental, occupational and criminal chemical exposure Use of the NPIS and TOXBASE Management of the poisoned patient in A&E Further information from: Rosie Spears or Gloria Alldridge tel: 02920 715554 or 02920 715013 Email: poisons rmation cardiffandvale.wales.nhs.
Find aciphex rabeprazole sodium ; medication description and details on prescription drug to check symptoms start here and ramipril.
Source: medicinenet rabeprazole, aciphex - clarifies the medication rabeprazole aciphex ; , a drug used for treating ulcers of the stomach and duodenum, gastroesophageal reflux disease gerd ; and zollinger-ellison syndrome.
Integrated management of childhood illnesses IMCI ; was developed by the World Health Organization WHO ; and UNICEF, and introduced in 1996 as the major strategy to improve children's health. IMCI comprises adequate institutional and community care against childhood illnesses, and nutrition, vaccination, and maternal health.1, 2 Different programs and policies have been implemented in Mexico in the past decades, with the and retin-a, for example, s rabeprazole.
Marijuana is not a narcotic and is not mentally or physically an addictive drug.
Cardiogenic shock complicating acute myocardial infarction is a challenging condition to treat. Vasopressors and inotropic agents required to increase perfusion pressure and cardiac output also increase myocardial oxygen demand5 and could potentially worsen ongoing myocardial ischaemia. Furthermore, these drugs may impair diastolic relaxation6 by increasing intracellular calcium concentration in myocytes. In contrast, levosimendan does not increase myocardial oxygen demand3 nor does it impair diastolic relaxation.2 These features in combination with its vasodilatory properties make levosimendan a promising agent in the management of patients with cardiogenic shock. In the patient described here, the observed baseline tachycardia was most likely a compensatory mechanism for the low cardiac output, and it was exacerbated by the b-adrenergic stimulant effects of dopamine and dobutamine. It is unlikely that the increase in HR was due to hypovolaemia since the patient's CVP remained at 78 mm for several hours after dobutamine was first administered. Despite an adequate CVP and dobutamine, the patient's CI remained very low. This may have been because the dobutamine dose was insufficient to improve cardiac performance, but it was not possible to increase the dose because of the patient's tachycardia. A higher dose of dobutamine could have increased the CI, but at the expense of increased HR and myocardial oxygen consumption, 5 both of which would have deleterious effects on the patient's underlying myocardial ischaemia. We chose to use levosimendan as it has been shown to be safe in patients with acute myocardial infarction, 4 it has antiischaemic effects7 and it does not increase myocardial oxygen consumption3 or have b-adrenergic stimulant effects. It was administered in a small loading dose8 of 6 mg kg1 to avoid the decrease in BP that has been observed with higher loading doses.4 There was a significant improvement in CI within 30 min of levosimendan administration, but HR increased. This is in keeping with the observations of and rimonabant.
But beyond the gates, over the lawns and behind the stolid brick exterior, king pharmaceuticals is a company riding out three years of tur-moil.
Rabeprazole tabs
Abstract 1472 THE GERMAN ADAPTATION OF THE CYSTIC FIBROSIS QUESTIONNAIRE: DATA SUPPORTING ITS SENSITIVITY TO CHANGE Kerstin Wenninger, Doris Staab, Heike Dittrich-Weber, Ulrich Wahn, Cystic Fibrosis Centre, Chest Clinic Heckeshorn, Berlin, Germany Cystic fibrosis CF ; is the most common genetic disease with a fatal outcome in industrialised countries. To date, the Cystic Fibrosis Questionnaire developed by Henry et al. in France is the only disease-specific instrument assessing health-related quality of life HRQOL ; for CF patients. Its reliability and validity has been supported by previous data. In a pilot study with 20 CF patients, differences on a number of CFQ scales before and after antibiotic treatment revealed preliminary support for the instruments sensitivity to change. The purpose of the present study was to collect further evidence for the instruments sensitivity to change by evaluating the effect of a climate health cure in Israel. 50 CF patients filled out the CFQ before and after their four week stay in Israel. Statistically significant improvements in HRQOL emerged on seven out of the thirteen scales, including physical functioning, energy level, emotional state, body image, subjective rating of health status, respiratory symptoms, and perception of threat and exhaustion by symptoms. Trends were found for feelings of shame regarding symptoms and for weight problems. The issue of clinical significance of these changes will be discussed and rivastigmine.
Mediated alpha1-adrenergic receptor dependent and independent actions may converge to augment some of the antiproliferative actions of this drug.
54 ; Title of the invention : PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED 1S, 4R ; 1-ACETOXY-4HYDROXYCYCLOPENT-2-ENE 51 ; International classification : C12P 7 62 71 ; Name of Applicant : 31 ; Priority Document No : 60 439, 953 ; PHARMACIA & UPJOHN COMPANY LLC 32 ; Priority Date : 14 01 2003 Address of Applicant : 301 HENRIETTA STREET, 33 ; Name of priority country : U.S.A. KALAMAZOO, MICHIGAN 49001, USA. U.S.A. 86 ; International Application No : PCT IB2004 000045 72 ; Name of Inventor : Filing Date : 05 01 2004 ; KEVIN EDWARD HENEGAR 87 ; International Publication No : WO 2004 063384 61 ; Patent of Addition to Application Number : NA Filing Date : NA 62 ; Divisional to to Application Number : NA Filing Date : NA 57 ; Abstract : This invention relates to a process for the synthesis of enantiomer-ically enriched IS, 4R ; of Formula I ; , a compound useful as an intermediate in the synthesis fo prostaglandins and prostanoids and sertraline.
While gonorrhea Neisseria gonorrhoeae, gonococcal, GC ; cases have reached an all-time national low, GC morbidity in California has been on the rise since 2000. Reported cases increased 19% in the first half of 2004, compared to the first half of 2003. Is the disease following suit in Merced County? Disturbingly, Merced has seen a 75% increase in cases during the same time period. Figure 1 below shows that GC rates in Merced are now nearing the state rate of roughly 80 cases per 100, 000 population. GC cases in Merced have increased steeply here for each of the last two years, from 71 cases in 2002 to 141 in 2003, and 185 cases in the first 11 months of 2004. The number of GC cases reported each month to MCDPH from 1998 to 2004 is depicted in Figure 2 see page 3 ; . Merced is one of 13 counties that had more than a 40% increase in cases in the past year. Six of these 13 counties, including Merced, lie in the Central Valley, making this an important regional issue. The Sexually Transmitted Disease STD ; Control Programs of these counties conferred with the California Department of Health Services CDHS ; STD Control Branch this Fall, to analyze data and compare features of these gonorrhea increases, and to develop strategies for control. One set of hypotheses contended that the increase in reported cases results from artifacts based on increased screening, more sensitive laboratory methods, or increased reporting. However, these hypotheses did not explain the excess cases, and were rejected. The increase of the past two years coincided with a shift into younger ages, including female and male teens. Before 2004, Merced County's female peak age group was 20-24 years. In 2004 to date, however, it has dropped to the 15-19 year age group. The male peak has remained at 20-24 years, but cases have shifted from older age groups into the 15-19 and 20-24 year groups. In the last two years, the largest numbers and steepest rates were in Hispanic females and males. However, in 2003 and 2004, cases in all ethnic groups went up. A large portion of the cases reported to MCDPH, especially in the past 2 years, are of unknown ethnicity, which often results from a case being reported by a laboratory, but not the physician. Laboratories typically do not report ethnicity. Reporting laws and regulations require reports from physicians for notifiable diseases, for example, parit rabeprazole.
Ace inhibitors are not only excellent drugs for high blood pressure, they also protect the heart and kidneys from the damage of hypertension and sildenafil.
And makes it the prime target for therapy. Regardless of primary stimulation, the production of acid by H-KATPase the proton pump ; is the final step for acid secretion and this step is inhibited by the PPIs.8 One dose of PPI inhibits acid production in about 70% of active pumps in the parietal cell. Acid secretion recovery occurs when new pumps are synthesised in the cell 36-72 hours later. Only active proton pumps are inhibited by PPIs. As not all the proton pumps are active at one time, one dose of PPI does not result in profound acid suppression. Subsequent PPI doses therefore inhibit the remaining active pumps. It takes five to seven days to achieve steady state. Of note, there is never complete inhibition of acid suppression because of continuous synthesis of new proton pumps.9 If PPIs are to be effective as an on-demand therapy, they should be taken for at least five to seven days. This also explains why weakened and alternate day regimens are not effective. COURSE OF PPIs Gastric acid hypersecretion is theoretically possible after these short courses of PPIs. A study from Scotland showed acid hypersecretion on discontinuing omeprazole after eight weeks of therapy. The clinical significance remained unknown.10 It is unclear if gastric acid hypersecretion provokes symptoms. If PPIs are administered twice daily, the more active proton pumps will be exposed to the drug, and steady state inhibition of gastric acid will be achieved more rapidly and will be more complete. If profound acid suppression is needed -- as in cases of severe erosive oesophagitis -- it is beneficial to give PPIs twice daily for a couple of days, to be continued once daily thereafter.9 Some patients might need long-term twice daily PPIs. The five available PPIs are omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole. All these agents are able to control GORD symptoms and heal oesophagitis when used at recommended dosages. The PPIs differ in their pKa, bioavailability, peak plasma level, rate of excretion and cost. The PPIs share a common structural motif, but vary in terms of their substitutions. The mode of action of PPIs is to inhibit the H-K-ATPase. The PPIs accumulate specifically and selectively in the secretory cannaliculus, the highly acid space of the parietal cell. Within that space, the PPIs undergo conversion to a reactive species, the thiophilic sulphenamide, which covalently bind to the cysteine residues on the alpha subunit of H-K-ATPase. This rate of conversion varies among the PPIs and is inversely proportional to their pKa: rabeprazole omeprazole esomeprazole lanzopraz ole pantoprazole. The pKa is 4 for omeprazole, esomeprazole and lansoprazole, 3.9 for pantoprazole and 5 for rabeprazole. Acid recovery depends on synthesis of new pumps and slow dissociation of PPIs from the cysteine residue. Differences in cysteine binding between PPIs may affect the speed of recovery.8 In vitro studies using rat microsomal membrane preparations containing H-K-ATPase have demonstrated that, in addition to cysteine 813, pantoprazole also binds to cysteine 822. Recovery of acid secretion following pantoprazole was prolonged compared to other PPIs possibly as a result of its binding to cysteine 822.11 Neither in vivo nor clinical studies have been performed to determine whether these observations are clinically relevant. STUDY RESULTS In terms of efficacy, all the available agents are remarkably effective. In one study, esomeprazole when given at a 20mg and 40mg dose and compared with 20mg omeprazole. This resulted in more effective acid control with reduced interpatient variability.12 In another study comparing esomeprazole with omeprazole in GORD patients with reflux oesophagitis, esomeprazole was more effective in healing and symptom resolution. When compared to lansoprazole 30mg, esomeprazole 40mg was found to be more effective in healing erosive oesophagitis and resolving heart burn.14 In a double-blind, placebo-controlled, three period, cross-over study, pantoprazole 40mg was significantly more effective than omeprazole 20mg in inhibiting meal-stimulated acid secretion. In addition, pantoprazole exhibited more rapid onset of action.15 Another double-blind, placebo-controlled, crossover study found that both lansoprazole 30mg and omeprazole 20mg induced potent and long-lasting acid inhibition with few minor differences.16 An independent Food and Drug Administration FDA ; panel concluded that, on a dose-adjusted basis, there was no statistically significant difference between esomeprazole and omeprazole for symptomatic GORD and erosive oesophagitis.17 An electronic database searched 32 randomised trials of higher quality. Differences were found between the standard doses of PPIs with regard to the onset of symptom relief in GORD lansoprazole was faster than omeprazole; esomeprazole was faster than both lansoprazole and omeprazole ; and healing of oesophagitis esomeprazole was superior to both lansoprazole and omeprazole ; .18 Despite these differences, there is as yet insufficient data to establish the superiority of any one agent over the others.
2 billion usd 191 million ; in fy06 driven primarily by sales of sertraline, rabeptazole and ramipril and simvastatin.
The therapeutic effects of rabepraz9le in patients with H. pylori positive or negative gastro-esophageal reflux disease.
Rabeprazole overdose
Rabeprazole was significantly better than ranitidine for healing duodenal ulcers p 0.17 ; . Healing rates were similar for both drugs. There was no significant difference after 4 weeks. Rrabeprazole patients had greater resolution of symptoms but this difference was not significant and sporanox.
Table 1. Pharmacokinetic Parameters of R ; - and S ; -Enantiomer of Lansoprazole and Rabepfazole in Renal Transplant Recipients and Healthy Subjects Renal transplant recipients Genotype EMs 28 days repeated dose Lansoprazole R ; -enantiomer Cmax ng ml ; Tmax h ; T 1 AUC ng h ml ; -enantiomer Cmax ng ml ; Tmax h ; T 1 AUC ng h ml ; AUC Rabepazole R ; -enantiomer Cmax ng ml ; Tmax h ; T 1 AUC ng h ml ; -enantiomer Cmax ng ml ; Tmax h ; T 1 AUC ng h ml ; AUC 30 mg 954552 3.91.5 2.31.0 , 3.31.3 1.20.6 , 451354 , 12.04.6 20 mg 18640 4.31.9 2.10.5.
15 2 Dressing Undressing Independence in dressing is defined as getting clothes from closets or drawers and putting them on including outer garments, and any braces required ; and managing fasteners such as buttons, snaps, hooks or zippers. If the only help someone gets is in tying shoes, do not count this as help. Aids which are commonly used in dressing include zipper pulls and specially designed clothing e.g. with Velcro fasteners ; . Consumers who dress themselves, but who require an inordinate amount of time to do so, should be scored "2" able with assistive devices difficulty ; . A distinction should be made between a consumer requiring some assistance in dressing such as getting the clothes from closets or zipping a back zipper and a consumer who needs to be dressed by a helper. If the consumer provides less than half of the effort needed for dressing, count that as dressed by others. 3. Grooming This item measures the consumer's ability to perform daily grooming tasks such as combing and brushing hair, brushing teeth, shaving males ; , and putting on makeup females ; . It is particularly important information for domiciliary or personal care homes placement. Eating This item refers to the consumer's ability to feed him or herself. It does not refer to meal preparation this is covered in the IADL section ; . Aids which may be used include special grip utensils or plates. A consumer may receive assistance with cutting food, and at the extreme, may need to be fed by another person. A distinction is made between the consumer who performs most of the effort required to eat, but who receives some assistance with eating, and a consumer who performs less than half the effort. 5. Transferring in and out of bed or chair This question measures the level of assistance the consumer needs in transferring. Special equipment used in transferring includes lifts, hospital beds, sliding boards, trapezes, or pulleys. It does not include using a cane, walker, or ordinary furniture for support. A consumer who is supported in getting in out of a bed or chair performs more than half of the work, should be scored "3B", hands-on-help. A consumer who needs maximum help, does not do at all or helper does more than half of all the activity, should be scored a "4". 6. Toileting These items are particularly important because individuals who have difficulty with toileting, and especially those with incontinence are at great risk of institutionalization. Some interviewers may feel uncomfortable asking consumers about difficulties with toileting. In fact, most elderly individuals are accustomed to questions like these, particularly if they have ever been hospitalized. It is and starlix and rabeprazole, for instance, raberazole sodium domperidone.
Study Suggests Conventional Antipsychotic Medications May Increase Risk of Death Among Elderly12-14 On April 11, 2005, the FDA issued a Public Health Advisory to alert healthcare professionals and patients to new safety information regarding the "off-label, " or unapproved, use of atypical antipsychotic medications. Examples of atypical.
Finland takes over the EU Presidency from Austria at the beginning of July. Close and smooth cooperation between the two countries gives the tune to Finland's presidency. According to Finland's Minister of Agriculture and Forestry, Juha Korkeaoja, it is a model that can be recommended to others as well. "Decision-making in the EU doesn't generally speaking run on the rails of fixed schedules and it normally takes several ministerial meetings to wrap up a legislative process. We are fully prepared to continue the processes dealt with during the Austrian presidency during our own term, if necessary." The two countries introduced a completely new practice by deciding to hold jointly some of the meetings of the high officials. The meetings of the Veterinary and Forest Directors were held in Austria, while the Directors of Fisheries and Paying Agencies will meet in Finland during the Finnish presidency." Austria and Finland have a lot in common in EU affairs, Juha Korkeaoja points out. The two countries agree that the Union's common agricultural policy must cover a wider range of issues than just the CAP payments under Pillar I. "In both Finland and Austria food production is only one albeit the most significant issue of living countryside. Getting this message across is more topical than ever as we are nearing the conclusion of the WTO negotiations. The themes of the unofficial ministerial meetings arranged during the two presidencies are links of the same chain. The meeting in Austria in May discussed the trends of rural policy in the EU, while the future of the European model of agriculture was selected as the theme for the meeting to be held in Finland in September." The last reforms of the common market systems, those concerned with fruit and vegetables and wine, will come up during the Finnish Presidency. Juha and sumatriptan.
Control group, which is likely to be far in excess of values currently deemed acceptable to healthcare funders. Because there are problems in interpreting confidence intervals around ICERs where data occupy more than one quadrant of the ICER plane, uncertainty is dealt with using the NMB approach and the generation of CEACs. The results of these analyses are presented below.
Other announcements and events that can impact the market price of the shares of our common stock include, without limitation: results of our clinical trials and preclinical studies, or those of our corporate partners or our competitors; regulatory actions with respect to our products or our competitors' products; achievement of other research or development milestones, such as completion of enrollment of a clinical trial or making a regulatory filing; our operating results; our product sales and product revenues; adverse developments regarding the safety and efficacy of our products, our product candidates, or third-party products that are similar to our products or our product candidates; developments in our relationships with corporate partners; 42 table of contents developments affecting our corporate partners; government regulations, reimbursement changes and governmental investigations or audits related to us or our products; changes in regulatory policy or interpretation; developments related to our patents or other proprietary rights or those of our competitors; changes in the ratings of our securities by securities analysts; operating results or other developments that do not meet the expectations of public market analysts and investors; purchases or sales of our securities by investors who seek to exploit the volatility of our common stock price; market conditions for biopharmaceutical or biotechnology stocks in general; and general economic and market conditions.
Approximately 53 percent of the seniors in the Deductible Plan will reach their annual deductible limit. This is a relatively high number of seniors considering that 25 percent of Deductible enrollees had no prescription purchases. During this program year, 37 percent of the Deductible seniors already reached their annual deductible, after having been enrolled for nine months at most. On average, seniors who reach their annual deductible purchase 45 prescriptions with an average drug cost of $2, 804. These seniors take approximately five months to reach their average annual deductible of $834, and they save $1, 615. Seniors with higher annual deductibles will take longer to reach their annual deductible limit, and a smaller percentage of them will reach their annual deductible, as illustrated in Figure 15.
SMC recommendation Advice: following a full submission Rabeprwzole is accepted for use within NHS Scotland for on-demand symptomatic treatment of moderate to severe gastro-oesphageal reflux disease GORD ; in patients without oesophagitis. It is the second proton-pump inhibitor PPI ; with a specific licence for on-demand therapy. Provided that there is a clearly defined need for maintenance therapy following acute treatment of GORD and that rabeprazole is considered to be the most appropriate PPI, on-demand use of rabeprazole is an effective treatment option in patients without oesophagitis. Tayside recommendation Not currently recommended pending formulary decision Points for consideration: The licence for rabeprazole has been extended to cover on-demand therapy in symptomatic moderate to very severe gastro-oesophageal reflux disease GORD ; . The licence excludes patients with oesophagitis. A single study of on-demand rabeprazole as maintenance therapy in GORD shows a lower rate of treatment discontinuation due to inadequate heartburn control versus placebo 6% versus 20% ; . With a placebo discontinuation rate of 20%, this study also shows that 4 patients in 5 were adequately controlled on placebo rescue antacids allowed ; . Rrabeprazole is more expensive than lansoprazole and generic omeprazole 44p per day for rabeprazole 10mg versus 42p for lansoprazole 15mg, 35p for omeprazole 10mg, and 39p for omeprazole 20mg ; . Omeprazole and lansoprazole are the PPIs of choice locally. Studies of on-demand omeprazole and lansoprazole also show significantly lower rates of treatment discontinuation versus placebo. Continued over.
The American Society for Pharmacology and Experimental Therapeutics encourages each Division to propose a Centennial Symposium to be presented at the Experimental Biology '08 meeting in San Diego. These Centennial Symposia will be reviewed by the Program Committee at the December 2006 meeting. All other symposia for the 2008 meeting will be reviewed under the normal schedule at the April 2007 meeting. A Centennial Symposium proposal differs from a regular symposium proposal in that it should have a short introductory talk that places the topic of the symposium in a historical context. This should be followed by 3-4 state-of-the-art scientific talks, of the caliber that one usually expects in a scientific symposium. Finally, there should be a short concluding talk that projects where this research is likely to lead AND the potential payoffs of this research to human health in the next 10 years. For the purposes of the Centennial Symposium only, the normal rule of requiring a speaker to speak for a minimum of 20 minutes in order to qualify for reimbursement will be waived to allow for reimbursement of the introductory and concluding speakers. However, if one of the other speakers is best qualified to present either of these talks, organizers are encouraged to use them for that purpose. As with all ASPET symposia, organizers are encouraged to consider the following: 1 ; Inclusion of qualified women and minority speakers. 2 ; Inclusion of a "translational" presentation bringing the basic science from "bench to bedside." 3 ; Topics applicable to multiple divisions, with joint sponsorship are encouraged. Organizers are encouraged to contact multiple divisions early in the planning process. A. Deadline for Submission For Centennial Symposia ONLY, the proposals are due in the ASPET office by November 15, 2006, to allow for processing in preparation for the Program Committee which will occur very shortly thereafter. Divisions may set their own deadlines earlier if they wish to receive and review multiple proposals. B. Content of Proposal for Symposium Because of the special nature of these symposia, it is expected that the Division leadership will be actively involved in the organization of these symposia. However, the content of the proposal itself does not differ significantly from the regular symposium proposal. The proposal should present reasons as to why the symposium is desirable and give details on the proposal. The total time assigned for presentations and discussions should not exceed two and one-half hours per symposium. The following points should be addressed in the proposal: 1. Proposed Title 2. Justification of need for an ASPET symposium on the particular topic. There will be a maximum of ten 10 ; Centennial Symposia, and the justification will be important in both the Division's and the Committee's evaluation. Thus justification should include the timeliness of the topic and and ramipril.
Rabeprazole alcohol
The wire lists all the latest results that are categorized as aciphex, rabeprazole generic.
Since C-1311 antitumor agent undergo enzymatic oxidative activation [2] and such activated drug binds irreversibly to DNA [3], we have focused our studies on the electrochemical oxidation of this compound on the search for the products of this reaction and on the detection of any adduct between C-1311 and DNA. Cyclic voltammetry and controlled potential electrolysis were employed for the study of C-1311 alone and in the presence of dG, the most probable C-1311 target of DNA structure. The obtained reaction mixtures were analysed by HPLC. It has been shown that two products of electrochemical oxidation, E1 and E2, are exactly alike to C1 and C2, the identified earlier products obtained after enzymatic activation of C-1311 [4]. The new product was found in the.
Talk your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.
|
